ACM
ADAR1 Capital Management Portfolio holdings
AUM
$616M
This Quarter Return
+12.59%
1 Year Return
+26.77%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$366M
AUM Growth
+$366M
(+64%)
Cap. Flow
+$93M
Cap. Flow
% of AUM
25.38%
Top 10 Holdings %
Top 10 Hldgs %
59.33%
Holding
282
New
118
Increased
35
Reduced
45
Closed
29
Top Buys
| 1 |
Alpha Architect 1-3 Month Box ETF
BOXX
|
$33.9M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
$25.5M |
| 3 |
Protagonist Therapeutics
PTGX
|
$16.9M |
| 4 |
Roivant Sciences
ROIV
|
$16.2M |
| 5 |
Cytokinetics
CYTK
|
$15.9M |
Top Sells
| 1 |
Keros Therapeutics
KROS
|
$23.2M |
| 2 |
Viking Therapeutics
VKTX
|
$19.7M |
| 3 |
Royalty Pharma
RPRX
|
$18.2M |
| 4 |
Merck
MRK
|
$7.09M |
| 5 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$6.35M |
Sector Composition
| 1 | Healthcare | 82.64% |
| 2 | Communication Services | 1.24% |
| 3 | Financials | 0.78% |
| 4 | Materials | 0.59% |
| 5 | Consumer Discretionary | 0.09% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Alpha Architect 1-3 Month Box ETF
BOXX
$7.91B
| $33.9M | 7.68% | +318,120 | New | +$33.9M |
|
|
2
Roivant Sciences
ROIV
$8.15B
| $29.4M | 6.68% | 2,791,870 +1,535,279 | +122% | +$16.2M |
|
|
3
Alnylam Pharmaceuticals
ALNY
$58.5B
| $26.9M | 6.11% | 180,145 +170,645 | +1,796% | +$25.5M |
|
|
4
Protagonist Therapeutics
PTGX
$3.67B
| $22.7M | 5.16% | 785,655 +584,796 | +291% | +$16.9M |
|
|
5
Cytokinetics
CYTK
$4.23B
| $22.4M | 5.08% | 319,510 +227,428 | +247% | +$15.9M |
|
|
6
Keros Therapeutics
KROS
$618M
| $22.4M | 5.08% | 338,243 -350,073 | -51% | -$23.2M |
|
|
7
Royalty Pharma
RPRX
$15.6B
| $21.9M | 4.97% | 721,301 -600,533 | -45% | -$18.2M |
|
8
BridgeBio Pharma
BBIO
$9.89B
| $17M | 3.86% | 549,804 +364,667 | +197% | +$11.3M |
|
|
MACK
9
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
| $13.3M | 3.02% | 902,350 +352,932 | +64% | +$5.21M |
|
10
Ascendis Pharma
ASND
$11.8B
| $7.34M | 1.67% | 48,584 +2,700 | +6% | +$408K |
|
11
Arbutus Biopharma
ABUS
$711M
| $5.35M | 1.21% | 2,074,183 -1,394,641 | -40% | -$3.6M |
|
|
TECX
12
Tectonic Therapeutic, Inc. Common Stock
TECX
$478M
| $5.06M | 1.15% | 3,954,857 +3,904,710 | +7,787% | +$5M |
|
|
ONC
13
BeOne Medicines Ltd. American Depositary Shares
ONC
$36.4B
| $4.93M | 1.12% | 31,505 +29,477 | +1,454% | +$4.61M |
|
14
Alkermes
ALKS
$4.78B
| $4.24M | 0.96% | +156,600 | New | +$4.24M |
|
|
BBOT
15
BridgeBio Oncology Therapeutics, Inc. Common Stock
BBOT
$708M
| $4.2M | 0.95% | +403,500 | New | +$4.2M |
|
16
Sarepta Therapeutics
SRPT
$1.78B
| $4.03M | 0.91% | 31,105 +23,043 | +286% | +$2.98M |
|
|
EDR
17
DELISTED
Endeavor Group Holdings, Inc.
EDR
| $3.99M | 0.91% | 155,250 +152,750 | +6,110% | +$3.93M |
|
18
Achieve Life Sciences
ACHV
$152M
| $3.98M | 0.9% | +875,000 | New | +$3.98M |
|
|
FUSN
19
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
| $3.78M | 0.86% | +177,200 | New | +$3.78M |
|
20
Absci
ABSI
$357M
| $3.33M | 0.76% | +586,984 | New | +$3.33M |
|
21
Edgewise Therapeutics
EWTX
$1.51B
| $3.3M | 0.75% | +180,911 | New | +$3.3M |
|
22
Fulcrum Therapeutics
FULC
$351M
| $3.21M | 0.73% | 339,825 -297,580 | -47% | -$2.81M |
|
23
Q32 Bio
QTTB
$20.9M
| $3.2M | 0.73% | 187,567 -106,109 | -36% | -$1.81M |
|
24
Applied Therapeutics
APLT
$71M
| $3.1M | 0.7% | +456,588 | New | +$3.1M |
|
25
SPDR Bloomberg 1-3 Month T-Bill ETF
BIL
$42.1B
| $2.98M | 0.68% | 32,500 +500 | +2% | +$45.9K |
|